Macquarie Group’s Quince Therapeutics QNCX Stock Holding History

Macquarie Group’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	-$3	–	2617
2022 Q1	$3	Hold	2	–	–	﹤0.01%	2606
2021 Q4	$6K	Hold	2	–	–	﹤0.01%	2563
2021 Q3	$40K	Hold	2	–	–	﹤0.01%	2293
2021 Q2	$23K	Hold	2	–	–	﹤0.01%	2340
2021 Q1	$16K	Sell	2 -1	-33%	-$7.2K	﹤0.01%	2327
2020 Q4	$16K	Hold	3	–	–	﹤0.01%	2255
2020 Q3	$29K	Hold	3	–	–	﹤0.01%	2083
2020 Q2	$27K	Buy	+3	New	+$27.5K	﹤0.01%	2089

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Macquarie Group's QNCX Position: Q2 2022 in Review

Macquarie Group sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 2 shares — an estimated $3 sold.

Macquarie Group first reported a position in QNCX in Q2 2020 and held it in 8 quarters. The position peaked at $40K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

Macquarie Group reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
Macquarie Group sold 2 Quince Therapeutics shares in Q2 2022, an estimated $3.
Macquarie Group first reported a position in Quince Therapeutics in Q2 2020 and held it in 8 quarters.
Macquarie Group's Quince Therapeutics position peaked at $40K in Q3 2021.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.